|1.||Doyle, Michael P: 2 articles (01/2005 - 10/2002)|
|2.||Corso, Carlos: 1 article (08/2007)|
|3.||Hermann, Joerg: 1 article (08/2007)|
|4.||Messmer, Konrad F: 1 article (08/2007)|
|5.||Raat, N J H: 1 article (11/2005)|
|6.||Liu, Jing-Feng: 1 article (01/2005)|
|7.||Klein, Jan: 1 article (01/2005)|
|8.||Raat, Nicolaas J H: 1 article (01/2005)|
|9.||Ince, Can: 1 article (01/2005)|
|10.||Burhop, Kenneth E: 1 article (01/2005)|
01/01/2005 - "In a fixed-pressure (40 mm Hg) rat model of hemorrhagic shock and resuscitation, rHb2.0 and albumin both restored mean arterial pressure (MAP) to baseline values, whereas rHb1.1 increased MAP to 27% above the baseline value. "
11/01/2005 - "Effects of recombinant-hemoglobin solutions rHb2.0 and rHb1.1 on blood pressure, intestinal blood flow, and gut oxygenation in a rat model of hemorrhagic shock."
01/01/2005 - "Effects of recombinant-hemoglobin solutions rHb2.0 and rHb1.1 on blood pressure, intestinal blood flow, and gut oxygenation in a rat model of hemorrhagic shock."
06/01/2004 - "The aim of this study was to compare the effects of two recombinant human hemoglobin solutions, a second-generation product bearing reduced nitric oxide-scavenging properties (rHb2.0) due to site directed mutagenesis of the heme pocket and a first-generation recombinant hemoglobin (rHb1.1) with scavenging capacity similar to native hemoglobin, on the pancreatic microcirculation after hemorrhagic shock. "
02/01/1997 - "To compare recombinant hemoglobin solution (rHb1.1) with colloid/blood (CB) resuscitation in a hemorrhagic shock (HS) model based on oxygen debt (O2D). "
06/01/1998 - "Resuscitation after hemorrhage using recombinant human hemoglobin (rHb1.1) in rats: effects on nitric oxide and prostanoid systems."
06/01/1998 - "The goals of the present study were two-fold: a) to determine the systemic and regional vascular effects of resuscitation with recombinant human hemoglobin (rHb1.1) in rats during controlled hemorrhage; and b) to determine whether nitric oxide (NO) or prostaglandins were involved in the observed responses. "
04/01/1997 - "The incidence of gastrointestinal symptoms, fever, and chills was greater after infusion of rHb1.1 than after HSA (P < 0.05). "
04/01/1997 - "Administration of rHb1.1 to conscious humans is associated with some side effects, such as gastrointestinal upset, fever, chills, headache, and backache."
|5.||Hypertension (High Blood Pressure)
10/01/2001 - "Hypertension resolved within 7 hours, and laboratory values returned to normal levels by day 7. Although the elevations in pancreatic enzymes seen in some rHb1.1-treated patients remain unexplained, the safety profile of rHb1.1 appears to be acceptable. "
10/01/2001 - "A slightly higher incidence of hypertension, symptoms suggestive of pyrogenicity, mildly elevated total and indirect bilirubin, and elevated pancreatic enzymes was observed in rHb1.1 treatment groups when compared with control. "
10/01/2001 - "To evaluate recombinant human hemoglobin (rHb1.1) in patients undergoing surgery involving general anesthesia; examine rHb1.1 for toxicity, including renal dysfunction and hypertension; and measure plasma concentrations of rHb1.1 over time. "
|1.||Nitric Oxide (Nitrogen Monoxide)
|6.||15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
|7.||Interleukin-6 (Interleukin 6)
|8.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)